Evidence map›Paper›PMID 41940182›Full record

ArticleEpilepsy & behavior reports2026

Drug resistant epilepsy driven by

Ann-Louise Esserlind, Annie Pedersen, Frida Abel, Tove Hallbook, Colin Reilly, Daniel Nilsson, Tatjana Liakina, Thomas Olsson Bontell

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Epilepsy & behavior reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ann-Louise EsserlindDepartment of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sweden.
Annie PedersenDepartment of Clinical Genetics and Genomics, Sahlgrenska University Hospital, Gothenburg, Sweden.
Frida AbelDepartment of Clinical Genetics and Genomics, Sahlgrenska University Hospital, Gothenburg, Sweden.
Tove HallbookDepartment of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sweden.
Colin ReillyDepartment of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sweden.
Daniel NilssonDepartment of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Tatjana LiakinaDepartment of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Thomas Olsson BontellDepartment of Clinical Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Malformations of cortical development (MCD), including focal cortical dysplasia type II (FCDII) and hemimegalencephaly (HME), are major causes of drug-resistant focal epilepsy (DRFE). Recent genetic discoveries implicate dysregulation of the mechanistic target of rapamycin (mTOR) signaling pathway as a key driver of abnormal cortical organization and epileptogenesis. Among these, somatic variants in Methods: We report a paediatric case with an extensive transmantle FCDIIb associated with a somatic Results: The identified mosaic Conclusions: This report expands the clinical and molecular spectrum of

Indexed as

Drug resistant focal epilepsyFocal cortical dysplasiamTORopathyNeurodevelopmental disordersPediatric epilepsyRHEBSomatic mosicism

Identifiers

PMID41940182
PMCPMC13049671

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.